Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole. [electronic resource]
Producer: 20070926Description: 325-33 p. digitalISSN:- 0167-6806
- Aged
- Anastrozole
- Androstadienes -- administration & dosage
- Antineoplastic Agents, Hormonal -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- economics
- Aromatase Inhibitors -- administration & dosage
- Breast Neoplasms -- drug therapy
- Chemotherapy, Adjuvant -- adverse effects
- Cost-Benefit Analysis
- Disease-Free Survival
- Drug Administration Schedule
- Drug Costs
- Female
- Humans
- Markov Chains
- Middle Aged
- Models, Economic
- Neoplasm Recurrence, Local -- prevention & control
- Nitriles -- administration & dosage
- Postmenopause
- Quality-Adjusted Life Years
- Tamoxifen -- administration & dosage
- Treatment Outcome
- Triazoles -- administration & dosage
- United States
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Validation Study
There are no comments on this title.
Log in to your account to post a comment.